Overview

Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)

Status:
Terminated

Trial end date:
2018-06-29

Target enrollment:

Participant gender:

Summary

The primary objective of this extension study (GS-US-312-0117) that is a companion study to Study GS-US-312-0116 (NCT01539512), is to evaluate the effect of idelalisib on the onset, magnitude, and duration of tumor control. Randomization was done in study GS-US-312-0116, and carried forward to study GS-US-312-117.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Idelalisib